Secrecy shrouds taxpayer-supported research [New Jersey]
By North Jersey Media Group,
North Jersey Media Group
| 06. 19. 2005
The church organist filled out a disclosure form.
So did the part-time bartender.
Both were required to disclose any jobs other than their positions with Rowan University, a state school.
Dr. Raphael Mannino, too, has employment beyond his public-sector position as an associate professor at the University of Medicine and Dentistry of New Jersey. He's an executive with one biotech start-up company and a paid board member of another.
But there's no disclosure form on file for him with the state Executive Commission on Ethical Standards. And there are none on file for anyone else at UMDNJ, or at either of the state's two other research universities.
Mannino is just one example of a hole in the system that ensures public interests, not private ones, are served by those involved in taxpayer-supported medical research.
Secrecy is important to the biotech industry, in both its business and research incarnations. After all, this is a world where the sole ownership of ideas is the basis of profits.
The picture is more complicated on the public side of the biotechnology partnership.
In particular...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...